BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy

DBV Technologies has submitted a biologics license application (BLA) to the FDA for the Viaskin peanut patch targeting children aged 4 to 7 with peanut allergies, supported by positive phase 3 VITESSE trial data showing significant desensitization benefits and mild side effects. The company has requested priority review after receiving breakthrough therapy designation, marking a key step toward regulatory approval for this non-invasive immunotherapy option.

This Wire brief sits within Fusion42's coverage of Biotech.